Search results for "anticoagulant treatment"

showing 3 items of 3 documents

Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus

2019

Background. Management of venous thromboembolism (VTE) in patients with haematologic malignancies and thrombocytopenia is clinically challenging due to the related risks. No prospective studies or clinical trials have been carried out and, therefore, no solid evidence on this compelling issue is available. Methods. Given this, an expert panel endorsed by the Gruppo Italiano Malattie Ematologiche dell'Adulto Working Party on Thrombosis and Haemostasis was set up to produce a formal consensus, according to the RAND method, in order to issue clinical recommendations about the platelet (PLT) cut-off for safe administration of low molecular weight heparin (LMWH) in thrombocytopenic (PLT <100×…

venous thrombosis thrombocytopenia blood cancer anticoagulant treatment consensusanticoagulantsblood cancerblood plateletsvenous thromboembolismthrombocytopeniaHeparin Low-Molecular-Weightheparinplatelet countanticoagulant treatmentSettore MED/15 - MALATTIE DEL SANGUEVenous thromboembolism haematological malignancythrombocytopeniaconsensuslow-molecular-weightOriginal Articlehematologic neoplasmscardiovascular diseasesvenous thrombosishumansanticoagulant treatment; blood cancer; consensus; thrombocytopenia; venous thrombosis; anticoagulants; blood platelets; heparin low-molecular-weight; humans; platelet count; consensus; hematologic neoplasms; thrombocytopenia; venous thromboembolismAnticoagulant treatment; Blood cancer; Consensus; Thrombocytopenia; Venous thrombosis
researchProduct

Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.

2015

Introduction: Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events. Many patients with AF receive chronic anticoagulation, either with vitamin K antagonists (VKAs) or with non-VKA oral anticoagulants (NOACs). We sought to analyze variables associated with prescription of NOAC. Methods: Patients with AF under anticoagulation treatment were prospectively recruited in this observational registry. The sample comprised 1290 patients under chronic anticoagulation for AF, 994 received VKA (77.1%) and 296 NOAC (22.9%). Univariate and multivariate analyses were performed to identify variables associated with use of NOAC. Results: Mean age was 73.8 ± 9.4 years, and 4…

MaleVitamin KClinical Decision-MakingMEDLINEAdministration OralHemorrhage030204 cardiovascular system & hematologyVitamin kanticoagulant treatment03 medical and health sciences0302 clinical medicineClinical decision makingFibrinolytic AgentsAtrial FibrillationmedicineHumansPharmacology (medical)030212 general & internal medicineAgedPharmacologyAged 80 and overbusiness.industrynonvitamin K antagonist oral anticoagulantsAnticoagulantsAtrial fibrillationMiddle Agedmedicine.diseasevitamin K antagonistsIncreased riskAnticoagulant therapyAnesthesiaOral anticoagulantFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct

Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study.

2012

Summary.  Background:  Little information is available on the long-term clinical outcome of cerebral vein thrombosis (CVT). Objectives and methods:  In an international, retrospective cohort study, we assessed the long-term rates of mortality, residual disability and recurrent venous thromboembolism (VTE) in a cohort of patients with a first CVT episode. Results:  Seven hundred and six patients (73.7% females) with CVT were included. Patients were followed for a total of 3171 patient-years. Median follow-up was 40 months (range 6, 297 months). At the end of follow-up, 20 patients had died (2.8%). The outcome was generally good: 89.1% of patients had a complete recovery (modified Rankin Scor…

AdultMalemedicine.medical_specialtyAnticoagulant treatment; Cerebral vein thrombosis; Mortality; Recurrence; Adult; Cerebral Veins; Cohort Studies; Female; Humans; Male; Middle Aged; Recurrence; ThrombosisCohort StudiesAnticoagulant treatment; Cerebral vein thrombosis; Mortality; RecurrenceRecurrenceInternal medicinemedicineRisk of mortalityHumansMED/41 - ANESTESIOLOGIAMortalitybusiness.industryIncidence (epidemiology)Cerebral Vein thrombosiHazard ratioCerebral VeinRetrospective cohort studyThrombosisHematologyMiddle Agedmedicine.diseaseThrombosisCerebral VeinsConfidence intervalSurgerycerebral vein thrombosisSettore MED/15 - MALATTIE DEL SANGUEThrombosiCohortFemaleAnticoagulant treatmentCohort StudiebusinessHumanCohort studyJournal of thrombosis and haemostasis : JTH
researchProduct